Corcept Therapeutics

Corcept Therapeutics, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with Cushing's syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
(Summary) (Company) (Chart)

4 September 2017
Price $16.80
1yr Target $14.20
Analysts 5
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain -15.48%
Yield 0.00%
1yr Tot Return -15.48%

P/E 84.00
PEG 1.15
Beta 2.06

EPS (ttm) $0.20
EPS next yr $0.69
Forward P/E 24.42
EPS next 5yr 73.20%
1yr Price Support $50.50

Market Cap $1.96 Bil
Revenues $108.70 Mil
Earnings $24.20 Mil
Profit Margin %

Quick Ratio 3.80
Current Ratio 4.00
Debt/Equity 0.07

1yr RevGR 61.71%
3yr RevGR 97.39%
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA 33.00%
ROE 51.40%

​My Path Forward

I started buying these shares near $10 per share with the intent of making a quick 20% gain. I've been adding more shares since then despite the fact that it continues to rise well past my initial estimate. This appears to be a very strong high growth stock in a sector that is exploding. I intend to continue to add shares in this company as well as other biotech companies in the near future. I believe we are on the cusp os a biotech revolution that will continue for decades. I intend to own shares of those companies that appear to be at the forefront of upcoming technologies. This company appears to be one of them.